| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | January 11, 2024 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
SEC declared Effectiveness of Vickers's registration statement on Form S-4Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is scheduled to be held on November 9, 2022, at 10:00 a.m., Eastern TimePost-closing company will be renamed "Scilex Holding Company" upon closing of the Business Combination, with common stock and warrants expected to trade on the Nasdaq Capital Market under the new ticker symbols "SCLX" and "SCLXW", respectively.Closing of Business Combination can provide up to approximately $100 million of gross cash proceeds in the trust (assuming no redemptions by Vickers Vantage shareholders and before expenses assoc
PALO ALTO, Calif. and SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it pre-emptively paid off and eliminated all of its remaining Notes in an aggregate principal amount of $67.7 million for a cash payment of approximately $39.7 million. Scilex is a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))). Scilex Holding Company and Vickers Vantage Corp. I (NASDAQ:VCKA) ("Vickers"), a special purpose acquisi
SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the FDA to discuss the SP-103 development plan and ensure collection of appropriate data needed to support drug approval.Eligibility for Accelerated Approval or Priority Review, if relevant criteria are met.Rolling Review, which means that Scilex can submit completed sections of its New Drug Application (NDA) for review by the FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. Despite an overall lack of evidence to support their efficacy, opioids continue to be prescribed to trea
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, to its Board of Directors. Governor Thompson's appointment is effective immediately. Governor Thompson currently serves as the Chief Executive Officer of Thomp
SAN DIEGO and PALO ALTO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), who is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that Elizabeth Czerepak will join the company as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective May 18, 2022. Ms. Czerepak will be a member of the Scilex and Sorrento Executive Leadership Teams, reporting to Scilex's Chief Executive Officer and President, Jaisim Shah, and Sorr
PALO ALTO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors. Ms. Hamill brings to the Scilex board more than three decades of experience in the biopharma industry, serving most recently as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc. Prior to
8-K - Scilex Holding Co (0001820190) (Filer)
EFFECT - Scilex Holding Co (0001820190) (Filer)
424B5 - Scilex Holding Co (0001820190) (Filer)
SC 13D/A - Scilex Holding Co (0001820190) (Subject)
SC 13D - Scilex Holding Co (0001820190) (Subject)
SC 13D/A - Scilex Holding Co (0001820190) (Subject)